Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy

Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016

(2017) Paul A. Bunn   JOURNAL OF CLINICAL ONCOLOGY

Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

(2017) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer

(2017) Jane Cullis et al.   Cancer Immunology Research

MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer

(2016) Riki Okita et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells

(2016) E. Beyranvand Nejad et al.   CANCER RESEARCH

Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies

(2016) Gwo Yaw Ho et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

(2016) Leonid Cherkassky et al.   JOURNAL OF CLINICAL INVESTIGATION

Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2016) Naiyer A. Rizvi et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer

(2016) Emma Eriksson et al.   Journal of Translational Medicine

Immunotherapy with methyl gallate, an inhibitor of Treg cell migration, enhances the anti-cancer effect of cisplatin therapy

(2016) Hyunseong Kim et al.   KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

(2016) Elisabeth Quoix et al.   LANCET ONCOLOGY

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

(2016) Corey J Langer et al.   LANCET ONCOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder

(2016) Alexander S. Baras et al.   OncoImmunology

Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells in a murine B16 melanoma model

(2015) Xiang Huang et al.   IMMUNOLOGIC RESEARCH

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer

(2015) Hidehito Horinouchi et al.   INVESTIGATIONAL NEW DRUGS

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

(2015) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer

(2015) Caicun Zhou et al.   JOURNAL OF CLINICAL ONCOLOGY

Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer

(2015) Cheng Chen et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma

(2015) Kyuichi Kadota et al.   Journal of Thoracic Oncology

Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)

(2015) Claudia Allemani et al.   LANCET

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice

(2015) Fei-Ting Hsu et al.   Oncotarget

Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course

(2015) An Coosemans et al.   OncoImmunology

Gemcitabine enhances antitumor efficacy of recombinant lipoimmunogen-based immunotherapy

(2015) Li-Sheng Chang et al.   OncoImmunology

Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer

(2015) Christopher R. Heery et al.   JAMA Oncology

Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence

(2014) A. R. de Biasi et al.   CLINICAL CANCER RESEARCH

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

(2014) Mark G. Kris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

(2014) Takashi Seto et al.   LANCET ONCOLOGY

Gemcitabine chemotherapy induces phenotypic alterations of tumor cells that facilitate antitumor T cell responses in a mouse model of oral cancer

(2014) Kei Tomihara et al.   ORAL ONCOLOGY

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

(2014) P. S. Adusumilli et al.   Science Translational Medicine

Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways

(2013) A. Sawant et al.   CANCER RESEARCH

Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer

(2013) Y. Homma et al.   Clinical & Translational Oncology

Modulation of peripheral immune responses by paclitaxel–ifosfamide–cisplatin chemotherapy in advanced non-small-cell lung cancer

(2013) Nikolaos Koufos et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model

(2013) A. Sevko et al.   JOURNAL OF IMMUNOLOGY

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial

(2013) Yi-Long Wu et al.   LANCET ONCOLOGY

Effects of conventional therapeutic interventions on the number and function of regulatory T cells

(2013) Mario Roselli et al.   OncoImmunology

Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo

(2012) Connie Jackaman et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Dose-Dense Chemotherapy Improves Mechanisms of Antitumor Immune Response

(2012) C.-L. Chang et al.   CANCER RESEARCH

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

(2012) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Impact of Immune Microenvironment in Stage I Lung Adenocarcinoma: Tumor Interleukin-12 Receptor β2 (IL-12Rβ2), IL-7R, and Stromal FoxP3/CD3 Ratio Are Independent Predictors of Recurrence

(2012) Kei Suzuki et al.   JOURNAL OF CLINICAL ONCOLOGY

Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cellsin vitroin a TLR4-independent manner

(2012) Tillmann Michels et al.   Journal of Immunotoxicology

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses

(2011) Sofia R. Gameiro et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Prognostic Immune Markers in Non–Small Cell Lung Cancer

(2011) Kei Suzuki et al.   CLINICAL CANCER RESEARCH

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

(2011) Elisabeth Quoix et al.   LANCET ONCOLOGY

CD4+Foxp3+ Regulatory T-cell Impairment by Paclitaxel is Independent of Toll-like Receptor 4

(2011) Y. Zhu et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Differential effects of Paclitaxel on dendritic cell function

(2010) Justin John et al.   BMC IMMUNOLOGY

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers

(2010) K. N. Kodumudi et al.   CLINICAL CANCER RESEARCH

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

(2010) Rupal Ramakrishnan et al.   JOURNAL OF CLINICAL INVESTIGATION

Synergistic Antitumor Effects of Regulatory T Cell Blockade Combined with Pemetrexed in Murine Malignant Mesothelioma

(2010) M. Anraku et al.   JOURNAL OF IMMUNOLOGY

Microtubule-Targeted Chemotherapeutic Agents Inhibit Signal Transducer and Activator of Transcription 3 (STAT3) Signaling

(2010) S. R. Walker et al.   MOLECULAR PHARMACOLOGY

Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism

(2009) G. V. Shurin et al.   JOURNAL OF IMMUNOLOGY

Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy

(2008) Lei Zhang et al.   CLINICAL IMMUNOLOGY

Dose translation from animal to human studies revisited

(2007) Shannon Reagan-Shaw et al.   FASEB JOURNAL